Patents by Inventor Sean ARMOUR

Sean ARMOUR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250228928
    Abstract: The present invention features methods utilizing nanoparticles for double-stranded DNA (dsDNA). The nanoparticles are able to deliver the dsDNA intracellularly where the dsDNA can stimulate the innate immune response. Uses of the described methods include enhancing an immune response to a vaccine and infectious disease treatment.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 17, 2025
    Inventors: Xavier ANGUELA, Sean ARMOUR, Pedro CEJAS, Ali NAHVI, Seoyun YUM, Rui ZHANG
  • Publication number: 20250221932
    Abstract: The present invention features methods utilizing nanoparticles for double-stranded DNA (dsDNA). The nanoparticles are able to deliver the dsDNA intracellularly where the dsDNA can stimulate the innate immune response. The provided methods can be used to treat cancer and be utilized in combination with different types of therapeutic agents having anti-cancer activity and with cancer vaccines.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 10, 2025
    Inventors: Xavier ANGUELA, Sean ARMOUR, Pedro CEJAS, Sonia GUEDAN, Ali NAHVI, Seoyun YUM, Rui ZHANG
  • Publication number: 20250101396
    Abstract: The invention provides nucleic acids encoding acid ?-glucosidase (GAA). In certain embodiments, nucleic acids have greater than about 86% sequence identity to a sequence selected from the group consisting of any of the sequences set forth as SEQ ID NOs: 1-5. In certain embodiments, nucleic acids encoding acid ?-glucosidase (GAA) contain less than 127 CpG dinucleotides. Expression cassettes, vectors, cells and cell lines and methods of using such nucleic acids encoding acid ?-glucosidase (GAA) are also provided.
    Type: Application
    Filed: September 9, 2024
    Publication date: March 27, 2025
    Inventors: Xavier Anguela, Sean Armour, Jayme Nordin
  • Publication number: 20240301380
    Abstract: Polynucleotides including nucleic acids encoding ?-galactosidase A (GLA) are described. Also described are expression cassettes, vectors, cells, and cell lines containing the polynucleotides, as well as methods of using the polynucleotides to treat lysosomal storage disorders such as Fabry disease.
    Type: Application
    Filed: January 13, 2022
    Publication date: September 12, 2024
    Inventors: Sean Armour, Daniel Cohen, Christopher Riling
  • Patent number: 12084693
    Abstract: The invention provides nucleic acids encoding acid ?-glucosidase (GAA). In certain embodiments, nucleic acids have greater than about 86% sequence identity to a sequence selected from the group consisting of any of the sequences set forth as SEQ ID NOs:1-5. In certain embodiments, nucleic acids encoding acid ?-glucosidase (GAA) contain less than 127 CpG dinucleotides. Expression cassettes, vectors, cells and cell lines and methods of using such nucleic acids encoding acid ?-glucosidase (GAA) are also provided.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: September 10, 2024
    Assignee: SPARK THERAPEUTICS, INC.
    Inventors: Xavier Anguela, Sean Armour, Jayme Nordin
  • Publication number: 20240110201
    Abstract: Nucleic acids encoding C1 inhibitor are described. Also described are expression cassettes, vectors, cells, and cell lines containing the nucleic acids, as well as methods of using the nucleic acids to treat complement-mediated disorders, such as hereditary angioedema.
    Type: Application
    Filed: January 27, 2022
    Publication date: April 4, 2024
    Inventors: Christopher Riling, Francis Pankowicz, Sean Armour, William John Quinn, III, Michael Preston, Stephen Ioele, Daniel Cohen, Zhenwei Kelvin See
  • Publication number: 20230241247
    Abstract: Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering an agent that blocks, inhibits or reduces the interaction between immunoglobulin G (IgG) and the neonatal Fc receptor (FcRn), such as an anti-FcRn antibody, to reduce IgG recycling and enhance IgG clearance in vivo. Also disclosed are methods for utilizing agents that reduce interaction of IgG with FcRn for gene therapy treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 3, 2023
    Applicant: SPARK THERAPEUTICS, INC.
    Inventor: Sean ARMOUR
  • Publication number: 20230142731
    Abstract: Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: July 12, 2022
    Publication date: May 11, 2023
    Inventors: Sébastien LACROIX-DESMAZES, Federico MINGOZZI, Jordan DIMITROV, Christian LEBORGNE, Sean ARMOUR
  • Publication number: 20210363192
    Abstract: The invention provides modified adeno-associated virus (AAV) capsid proteins. Modified AAV capsid proteins include, for example, capsid proteins modified to have a peptide insertion comprising a nuclear localization signal (NLS) sequence, capsid proteins modified to have an amino acid substitution at an RXXL site or a (L/P)PXY site, where X can be any amino acid, and capsid proteins modified to have one or more particular amino acid positions substituted with a different amino acid.
    Type: Application
    Filed: April 26, 2019
    Publication date: November 25, 2021
    Applicant: SPARK THERAPEUTICS, INC.
    Inventors: Xavier ANGUELA, Sean ARMOUR, Nicholas KEISER, Suryanarayan SOMANATHAN, Mustafa N. YAZICIOGLU
  • Publication number: 20210246469
    Abstract: Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: April 7, 2021
    Publication date: August 12, 2021
    Inventors: Sébastien LACROIX-DESMAZES, Federico MINGOZZI, Jordan DIMITROV, Christian LEBORGNE, Sean ARMOUR
  • Publication number: 20210228738
    Abstract: Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: July 17, 2017
    Publication date: July 29, 2021
    Inventors: Sébastien LACROIX-DESMAZES, Federico MINGOZZI, Jordan DIMITROV, Christian LEBORGNE, Sean ARMOUR
  • Publication number: 20210222141
    Abstract: The invention provides nucleic acids encoding acid a-glucosidase (GAA). In certain embodiments, nucleic acids have greater than about 86% sequence identity to a sequence selected from the group consisting of any of the sequences set forth as SEQ ID NOs:1-5. In certain embodiments, nucleic acids encoding acid a-glucosidase (GAA) contain less than 127 CpG dinucleotides. Expression cassettes, vectors, cells and cell lines and methods of using such nucleic acids encoding acid a-glucosidase (GAA) are also provided.
    Type: Application
    Filed: May 15, 2019
    Publication date: July 22, 2021
    Applicant: SPARK THERAPEUTICS, INC.
    Inventors: Xavier ANGUELA, Sean ARMOUR, Jayme NORDIN